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Allogeneic hematopoietic cell transplantation (HCT) represents a potentially curative treatment modality for several hematologic malignancies. Conventional myeloablative conditioning regimens are associated with high treatment-related mortality. To this end, the introduction of nonmyeloablative (NMA) conditioning implies that older and more frail patients can be offered HCT, and recent data suggest comparable outcome of conventional and NMA-HCT, both with regards to efficacy and side effects, at least for selected indications. 1 The curative principle in allogeneic HCT with NMA conditioning is solely related to the graft-versus-leukemia (GVL) effect, and several lines of evidence strongly suggest that donor T cells are the main effectors. In human leukocyte antigen (HLA), identical sibling HCT, T-cell responses to minor histocompatibility antigens (mHags) areFat least in partFresponsible for the GVL effect but also cause graft-versushost disease (GVHD). GVHD represents a major side effect of HCT, and it is well established that there exists correspondence between the GVL effect and GVHD. As a consequence, increased knowledge concerning mechanisms at play and the targets recognized may set the stage for development of treatment strategies that focus on induction of GVL in the absence of GVHD. 2 Obviously, increased insight into the cells, molecules and antigens involved with GVL and GVHD are important to possibly be able to control and direct these events more precisely.
mHags are known to represent prominent target structures in the HCT setting. 3 In general, mHags may derive from antigens expressed on the male Y chromosome, or from polymorphic proteins encoded on autosomal chromosomes. A limited number of mHags has been characterized, but the HA-1 and HA-2 antigensFderived from nucleotide polymorphisms in proteins of hematopoietic lineageFhave been shown to represent prominent targets at mismatch and therefore represent ideal target structures that could be used in a therapeutic setting, for example, vaccination in combination with HCT. 4 However, the practical applicability of single nucleotide polymorphism derived mHags in cancer therapy obviously depends on the frequencies of the individual single nucleotide polymorphism in the population, which for several of the characterized mHags are quite low. 3, 5 Moreover, the frequencies of these mHags display significant differences among populations even in Europe. 6 Conversely, Histocompatibility Y (HY)-derived mHags are relevant also in practical terms as this group of antigens are potentially relevant in all female to male HCT, although it should be mentioned that female to male HCT is preferentially avoided due to a higher risk of GVHD. Concerning Y chromosome encoded mHags, the Y-chromosomal protein SMCY-derived mHag restricted by HLA-A2.01; FIDSYICQV (HY-A2) 7 could represent an important target as data from other studies suggested the dominance of this antigen at parity for HA-1/2 antigens. [8] [9] [10] We studied T-cell clonality and anti-chronic lymphocytic leukemia (CLL) reactivity in two CLL patients receiving HLAidentical NMA-HCT. In an attempt to address the frequency of CLL reactive T cells, we demonstrated that approximately 10% of the T cells gained cytotoxic features (surface expression of CD107a) upon coculture with autologous ex vivo CLL cells in one of the patients (UPN 766). Genotyping of donor and recipient revealed that they were matched for the mHags HA-1, 2 and 8. However, as the male recipient was transplanted with his HLA-identical sister, HY could play a central role. Thus, we used an HLA-A2 dextramer coupled with the HY-A2 to analyze the frequency of HY-specific CD8 þ T cells in UPN 766. The specific binding of the dextramer was verified by staining of an HY-A2 specific T-cell clone ( Figure 1a ). The dextramer analyses of peripheral blood mononuclear cells from UPN 766 showed that only 0.2% of CD8 þ T cells (compared to approximately 10% being CD107a CD8 þ T cells upon CLL stimulation), were specific for HY in HLA-A2 context. 11 We, therefore, analyzed male patients that received HLAidentical NMA-HCT from their female sibling. To facilitate comparative studies, patient/donor pairs should be HLA-A2 positive and be characterized by parity for HA-1, HA-2 and HA8Fall of which give rise to HLA-A2 restricted peptides that might be dominant over HY. A total of six pairs of donors and patients (including our previous analyses of one pair) matched the above criteria and were studied by Major Histocompatibility Complexes (MHC) dextramers for the presence of HY-specific CD8 þ T cells among the peripheral blood mononuclear cells.
Concerning HY-A2-specific CD8 þ T cells in the donors, three of these harbored rather high frequencies, ranging from 0.1 to 0.2% of CD8 þ T cells (Table 1 ). The remaining donors had a precursor frequency close to zero. Strikingly, analyses of the HY frequency in the recipients post transplant showed a very low to borderline presence of HY-A2-specific T cells (o0.01%) in four out of six patients, with the remaining two recipients harboring 0.1 and 0.2% HY-A2-specific T cells. Summing up, four out of six recipientsFmatched for HA-1, 2, and 8Fwere characterized by the absence or borderline frequency of HY-A2-specific CD8 þ T cells in peripheral blood mononuclear cells post HCT, despite the fact that these cells are readily detectable among women following pregnancy with a male fetus. [12] [13] [14] To the latter point, our own analyses of five healthy women with at least one son gave similar results detecting HY-A2-specific T cells (data not shown). It has been shown that the frequencies of mHagspecific CD8 þ T cells may fluctuate immensely over time, 15 which in part could explain the detected low frequency of HY-A2-specific T cells. However, at least concerning patient 766, absence of HY-A2 reactivity was concurrent with significant overall reactivity. 11 Reactivity, in the context of HLA-B7 could potentially be relevant; 16 however, none of the patients expressed this HLA molecule (Table 1) .
Regarding patient 766 and the corresponding donor, HY-A2-specific T cells were undetectable by MHC dextramer fluorescent activated cell sorting analyses in the donor (Table 1) . Thus, these data strongly suggest that this response was elicited in the recipientFalbeit only reaching a very minor frequency of the CLL-reactive T cells. To gain information as to the phenotype of HY-specific T cells, we analyzed these cells for expression of CCR7 and CD45RO/RA. The results of this analysis demonstrated that the cells expressed the CD45RO isoform were mainly CCR7 negative, thus were antigen experienced CD8 þ T cells of effector memory phenotype (Figure 1b) .
Evidently, the HY-A2 peptide is processed and expressed in the context of HLA molecules on the surface of male-derived cells. The peptide is characterized by quite high-binding affinity to the HLA molecule and a subset of memory T cells specifically recognizes the peptide. Moreover, HY-specific T cells are present in a significant fraction of female donors that would be expected to further aid the generation of a high-frequency T-cell response in the patient. 13 Thus, the biology of HY-specific T-cell responses as well as the biochemical properties of the HY peptide comprises characteristics that would be expected to elicit powerful responses in the recipient. Nevertheless, it is apparent that the elicited reactivity may be very low, despite high overall antitumor reactivity, raising the question of which molecular and cellular determinants direct or influence the dominance ofFor lack ofFa given peptide following HCT.
Characterization of mHags offers the potential to target these antigens in a therapeutic setting. Obviously, knowledge concerning the dominance of particular mHags might represent an important parameter, to select mHags both for studies of the biology of HCT as well as for decision making regarding the strategies for specific targeting. However, the parameters that control immunity to mHags remain largely unknown. In a murine study, immunodominance was shown to be regulated at different levels, 9 but it is questionable to which extend studies of inbreed strains of mice can be extrapolated to the human setting. In CD8 þ T-cell responses to viral antigens, immunodominance seems to be much less relevant in secondary compared to primary responses, 17 whereas this seems not to be the case for mHag. However, concerning HCT in humans, CD8 þ memory T cells specific for mHags may very well be present in the transplant, and to our knowledge, individual specific T-cell clonotypes have not been tracked from donor to patient, thus, whether the response in the patient is primary or secondary is not known.
Our data suggest thatFeven when dominant antigens such as HA-1 are irrelevantFresponses against HY-A2 are not frequent, despite the presence of such specific T cells in the transplant. Considering the limited number of patient/donor pairs in this study, this notion can be further elucidated by studying different ethnic populations, the frequency of known polymorphisms, biological responses and the outcome of HCT. 18 In particular, combining genetic mapping and data from biological monitoringFideally of donors as well as recipientsFmay provide novel insight into the mechanisms that govern immunodominance among different mHag responses and the distinction between immunity and tolerance. To the latter, it has been found that mHag-specific responses may comprise two functionally different populations; one being regulatory T-cells secreting IL-10, another constituting conventional effector T cells. 19 Thus, the presence of mHag-specific memory T cell in the transplant could comprise regulatory cells. Nevertheless, Letters to the Editor available data demonstrate that in general previous immunization in the donor represent a risk factor in relation to GVH responses. 20, 21 In this respect, in high-risk transplantations such as from female to male, allografting is followed by intense pharmacological immunosuppression, which in some cases successfully prevents the development of GVHD and induces tolerance that obviously influences the biological readout as well.
The data presented herein suggest that responses against the HLA-A2-restricted peptide FIDSYICQV may not be frequently elicited after HLA-matched sibling HCT. This underlines the importance of scrutinizing the cellular and molecular mechanisms that govern immunodominance during HCT, in particular, whether priming of precursor T cells in the donor influences or whether the presence of a given antigen leads to tolerance or immunity. 22 Our data highlight the importance of characterizing novel mHagsFin turn setting the stage for more detailed analyses of patients receiving HCTFand possibly offering the means to modify GVHD and the GVL effect-associated responses following HCT. In particular, as responses against some mHags are more prone to influence the severity of GVHD, further insight into these issues may set the stage for including matching of mHags in HCT.
